利弊权衡:英国国家筛查委员会最新前列腺癌筛查审查
英国国家筛查委员会(UK NSC)于2025年启动前列腺癌筛查综合审查,委托定制经济模型评估全人群筛查和高危人群靶向筛查策略。基于建模和利益相关方咨询,UK NSC建议反对全人群筛查及大多数靶向人群筛查,仅推荐对有乳腺癌、卵巢癌、胰腺癌或前列腺癌家族史的致病性BRCA2变异男性进行筛查,认为这是唯一筛查利大于弊的群体。
要点
- UK NSC推荐反对全人群前列腺癌筛查及大多数靶向人群筛查。
- 仅推荐筛查携带致病性BRCA2变异且有相关家族史的男性。
- 该群体前列腺癌更具侵袭性,是唯一筛查利大于弊的群体。
核心结论
- UK NSC建议反对全人群前列腺癌筛查和大多数靶向人群筛查,仅推荐对特定BRCA2变异携带者进行筛查。
研究设计与样本
- 叙述性综述,描述UK NSC 2025年前列腺癌筛查审查过程,基于委托的定制经济模型和利益相关方咨询。
主要发现
- 模型评估了全人群筛查和高危男性靶向筛查策略,UK NSC基于建模和咨询做出推荐。
- UK NSC仅对携带致病性BRCA2变异且有乳腺癌、卵巢癌、胰腺癌或前列腺癌家族史的男性筛查有把握认为利大于弊。
关键数值与推荐
- UK NSC推荐反对全人群筛查和大多数靶向人群筛查。
- UK NSC推荐对携带致病性BRCA2变异且有乳腺癌、卵巢癌、胰腺癌或前列腺癌家族史的男性进行筛查。
临床怎么用
- 临床中不应开展全人群前列腺癌筛查,可考虑对特定BRCA2变异携带者及家族史阳性男性进行筛查。
局限性
- 本文为叙述性综述,未报告建模的具体数据、阈值或长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate cancer is the most common type of cancer in men but there is no national screening programme in the UK or in most other countries. The UK National Screening Committee (UK NSC) is the independent advisory body responsible for providing evidence-based recommendations to ministers in the four UK nations regarding screening programmes. Following the expansion of its remit to include targeted screening (2022) and the publication of new long-term trial data, the UK NSC launched a comprehensive review of prostate cancer screening in 2025. To inform this review, a bespoke economic model was commissioned, drawing on best available evidence and input from clinicians, technical experts, and patient representatives. The model evaluated whole-population screening and targeted strategies for men at higher risk. Based on the modelling study and consultation with stakeholders, the UK NSC recommended against whole-population screening and screening in most targeted groups. The UK NSC has recommended screening for men with a pathogenic BRCA2 variant with a family history of breast, ovarian, pancreatic, or prostate cancer. This was the only group where the UK NSC had confidence that screening would do more good than harm, primarily because prostate cancer tends to be more aggressive in this group. This narrative review describes the process taken by the UK NSC in developing its recommendations and highlights where additional evidence is still needed.
引用
- Boshari T, Anderson A, Richards M, et al. More harm than good? The UK National Screening Committee's latest review of prostate cancer screening. BJU Int. 2026. PMID: 42259762. doi:10.1111/bju.70355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。